BioLife Solutions, Inc. reaffirmed earnings guidance for the fiscal 2023. For the period, the company expected revenue to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.56 USD | +0.29% | -1.76% | +26.95% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.95% | 944M | |
-5.22% | 182B | |
-4.37% | 102B | |
-4.67% | 66.74B | |
-8.61% | 45.55B | |
+10.30% | 44.89B | |
+6.13% | 40.62B | |
+17.51% | 30.04B | |
+14.80% | 24.34B | |
-5.87% | 23.95B |
- Stock Market
- Equities
- BLFS Stock
- News BioLife Solutions, Inc.
- Biolife Solutions, Inc. Reaffirms Earnings Guidance for the Fiscal 2023